ORIC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ORIC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pretax income is the income that a company earns before paying income taxes. ORIC Pharmaceuticals's pretax income for the three months ended in Sep. 2024 was $-34.57 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-119.87 Mil. ORIC Pharmaceuticals's pretax margin was %.
The historical data trend for ORIC Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORIC Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Pre-Tax Income | Get a 7-Day Free Trial | -26.88 | -73.70 | -78.72 | -89.12 | -100.70 |
ORIC Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Pre-Tax Income | Get a 7-Day Free Trial | -25.48 | -28.33 | -25.01 | -31.96 | -34.57 |
For the Biotechnology subindustry, ORIC Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ORIC Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where ORIC Pharmaceuticals's Pre-Tax Income falls into.
This is the income that a company earns before paying income taxes.
ORIC Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | -110.78 | + | 10.083 | + | 0 | + | 0 | + | 0 | |
= | -100.70 |
ORIC Pharmaceuticals's Pretax Income for the quarter that ended in Sep. 2024 is calculated as
Pretax Income | = | Operating Income | + | Non Operating Income | + | Interest Expense | + | Interest Income | + | Other |
= | -38.318 | + | 3.752 | + | 0 | + | 0 | + | -7.105427357601E-15 | |
= | -34.57 |
Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORIC Pharmaceuticals (NAS:ORIC) Pre-Tax Income Explanation
ORIC Pharmaceuticals's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as
Pretax Margin | = | Pretax Income | / | Revenue |
= | -34.566 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of ORIC Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Jacob Chacko | director, officer: President and CEO | C/O IGNYTA, INC., 11095 FLINTKOTE AVE., SUITE D, SAN DIEGO CA 92121 |
Pratik S Multani | officer: Chief Business Officer | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Dominic Piscitelli | officer: Chief Financial Officer | C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121 |
Pfizer Inc | 10 percent owner | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
Column Group Llc | 10 percent owner | 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129 |
Column Group Ii Gp, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Peter Svennilson | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Column Group Ii, Lp | 10 percent owner | 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
David V Goeddel | 10 percent owner | C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158 |
Angie You | director | C/O AMUNIX PHARMACEUTICALS, INC., 2 TOWER PLACE, #1100, SOUTH SAN FRANCISCO CA 94080 |
Richard A. Heyman | director | 5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121 |
Steven L. Hoerter | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Richard H Scheller | director | C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired • 10-04-2024
By GuruFocus Research • 03-13-2024
By GuruFocus News • 11-13-2024
By GuruFocus Research • 03-01-2024
By GlobeNewswire • 09-06-2024
By Marketwired • 11-01-2024
By GuruFocus Research • 03-01-2024
By Marketwired • 08-12-2024
By Marketwired • 04-15-2024
By Marketwired • 07-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.